Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non–Small Cell Lung Cancer Xenograft Models
Conclusions: MDM2 small-molecule inhibitor is effective in treating NSCLC tumors with wild-type p53, supporting further clinical investigation as a potential NSCLC therapy.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Lung Cancer | Nanotechnology | Non-Small Cell Lung Cancer | Oral Cancer